91 related articles for article (PubMed ID: 12796596)
1. Oncogenes in male breast cancer.
Idelevich E; Mozes M; Ben-Baruch N; Huszar M; Kruglikova A; Katsnelson R; Shani A
Am J Clin Oncol; 2003 Jun; 26(3):259-61. PubMed ID: 12796596
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
3. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
Logullo AF; Lopes AB; Nonogaki S; Soares FA; Netto MM; Nishimoto IN; Brentani MM
Oncol Rep; 2007 Jul; 18(1):121-6. PubMed ID: 17549356
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of bcl-2 in UICC stage I and III colorectal carcinoma patients: correlation with c-erbB-2, p53, ki-67, CD44, laminin and collagen IV in evaluating prognostic significance.
Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
Pol J Pathol; 2006; 57(3):149-59. PubMed ID: 17219742
[TBL] [Abstract][Full Text] [Related]
5. [Comparative study of P 53, Bcl-2, and C-erbB-2 expression in low-grade papillary bladder tumors].
Ramos Soler D; Navarro Fos S; Villamón Fort R; Gil Salom M; Llombart Bosch A
Arch Esp Urol; 2003 Apr; 56(3):277-85. PubMed ID: 12768988
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer].
Wang Y; Zhang XR; Fu J; Tan W; Zhang W
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):369-72. PubMed ID: 15312350
[TBL] [Abstract][Full Text] [Related]
7. The significance of c-erbB-2 overexpression and p53 expression in patients with axillary lymph node--negative breast cancer: a tissue microarray study.
Ko SS; Na YS; Yoon CS; Park JY; Kim HS; Hur MH; Lee HK; Chun YK; Kang SS; Park BW; Lee JH
Int J Surg Pathol; 2007 Apr; 15(2):98-109. PubMed ID: 17478762
[TBL] [Abstract][Full Text] [Related]
8. Relationship between AgNORs, MIB-1 and oncogene expression in male breast carcinoma and papillary superficial bladder neoplasm.
Pich A; Margaria E; Chiusa L; Bortolin P; Palestro G
Oncol Rep; 2003; 10(5):1329-35. PubMed ID: 12883702
[TBL] [Abstract][Full Text] [Related]
9. Bcl2, p53 and clinical outcome in a series of 138 operable breast cancer patients.
Castiglione F; Sarotto I; Fontana V; Destefanis M; Venturino A; Ferro S; Cardaropoli S; Orengo MA; Porcile G
Anticancer Res; 1999; 19(5C):4555-63. PubMed ID: 10650810
[TBL] [Abstract][Full Text] [Related]
10. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of bcl-2 in Dukes' stage B and C colorectal carcinoma patients: correlation with p53 and ki-67 in evaluating prognostic significance.
Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
Pol J Pathol; 2005; 56(4):179-85. PubMed ID: 16477877
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
13. p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer.
Têtu B; Brisson J; Plante V; Bernard P
Mod Pathol; 1998 Sep; 11(9):823-30. PubMed ID: 9758361
[TBL] [Abstract][Full Text] [Related]
14. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.
Yamashita H; Nishio M; Toyama T; Sugiura H; Zhang Z; Kobayashi S; Iwase H
Breast Cancer Res; 2004; 6(1):R24-30. PubMed ID: 14680497
[TBL] [Abstract][Full Text] [Related]
15. Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival.
Pich A; Margaria E; Chiusa L
J Clin Oncol; 2000 Aug; 18(16):2948-56. PubMed ID: 10944127
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of two androgen-induced markers (apolipoprotein D and pepsinogen C) in female and male breast carcinoma.
Serra C; Vizoso F; Lamelas ML; Rodríguez JC; González LO; Merino AM; Baltasar A; Pérez-Vázquez MT; Medrano J
Int J Surg Investig; 2000; 2(3):183-92. PubMed ID: 12678518
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma.
Ferrari S; Bertoni F; Zanella L; Setola E; Bacchini P; Alberghini M; Versari M; Bacci G
Cancer; 2004 May; 100(9):1936-42. PubMed ID: 15112275
[TBL] [Abstract][Full Text] [Related]
18. Clinical contribution of bcl-2, p53 and Ki-67 proteins in pancreatic ductal adenocarcinoma.
Mäkinen K; Hakala T; Lipponen P; Alhava E; Eskelinen M
Anticancer Res; 1998; 18(1B):615-8. PubMed ID: 9568186
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of p53 and c-erbB-2 immunohistochemical evaluation in colorectal adenocarcinoma.
Lazaris AC; Theodoropoulos GE; Anastassopoulos P; Nakopoulou L; Panoussopoulos D; Papadimitriou K
Histol Histopathol; 1995 Jul; 10(3):661-8. PubMed ID: 7579815
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer.
Tsutsui S; Yasuda K; Suzuki K; Takeuchi H; Nishizaki T; Higashi H; Era S
BMC Cancer; 2006 Jul; 6():187. PubMed ID: 16839413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
